Fosun Pharma receives approval of supplementary drug application slots issued by the State Drug Administration

recently, Shanghai FosunPharmaceutical(http://(Group) limited shares
company(http://(hereinafter referred to as "Fosun Pharma"), its controlling subsidiary Shenyang Red Flag
Pharmaceutical(http://Co., Ltd(hereinafter referred to as "Shenyang Red Flag")," received the StatePharmaceutical(http://The Administration ofof the "Supplemental Application for Pharmaceutical Sico" (spec: 0.3g)Prior to that, Shenyang Red Flag received the State Drug Administration issued on isoniazid tablets (spec: 0.1g) of the "drug supplementary application approval", coupled with the approved specifications, meaning that the drug (0.1g and 0.3g specifications) have passed the generic consistency evaluationAccording to the announcement, isoniazid tablets are mainly used in combination with other anti-TB drugs, suitable for the treatment of various types of tuberculosis, is the national basicdrug(http://, the national health insurance catalog Class A varietiesAccording to the State Drug Administration data, isoniazid tablets have 568 approvals, specifications of 0.05g, 0.1g and 0.3gIn addition to Shenyang Red Flag (0.1g and 0.3g specifications) isoniazid tablets through the consistency evaluation, the company's wholly-owned subsidiary of the pharmaceutical industry, South China Pharmaceuticals developed isoniazid tablets (tablets, 100mg) also passed the consistency evaluation